Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ: MCRB )

0.9241 -0.0359 (-3.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
From Seres Therapeutics
Via Business Wire
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
From Seres Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
Analyst Ratings For Seres Therapeutics
Within the last quarter, Seres Therapeutics (NASDAQ:MCRB)... 
Via Benzinga
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
53 Biggest Movers From Yesterday
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Why Seres Therapeutics Stock Is Soaring Today
The company completed its target enrollment in a pivotal clinical study. 
Via The Motley Fool
Why Seres Therapeutics Shares Are Trading Higher Today
Seres Therapeutics (NASDAQ:MCRB) shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109. Seres... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 211.66% to $22.04 during Wednesday's regular session. The market value of their outstanding shares... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Seres Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 29 stocks hit new 52-week lows. Significant Points: Campbell Soup (NYSE:CPB) was the biggest company by market cap to set a new 52-week low.... 
Via Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols (NASDAQ:GRFS) was the largest firm by market cap to set a new 52-... 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was Koninklijke Philips (NYSE... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Recap: Seres Therapeutics Q2 Earnings
Shares of Seres Therapeutics (NASDAQ:MCRB) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 89.29... 
Via Benzinga
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
From Seres Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.